# Deciphering the contribution of 5’-tiRNA- Lys-CTT as an emerging early diagnostic biomarker for hepatocellular carcinoma

## TL;DR

This paper explores the potential of a specific tRNA-derived RNA, 5’-tiRNA-Lys-CTT, as a new biomarker for early detection of liver cancer.

## Contribution

The paper highlights the novel role of 5’-tiRNA-Lys-CTT as a promising early diagnostic biomarker for hepatocellular carcinoma.

## Key findings

- 5’-tiRNA-Lys-CTT is a stable tRNA-derived RNA with potential for liquid biopsy in HCC detection.
- It offers improved sensitivity and specificity over current diagnostic methods like AFP.
- Recent advancements suggest its use could enhance early detection and personalized therapy for HCC.

## Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, with early detection critical for improving survival rates. Late-stage diagnosis contributes to dismal prognosis. Current surveillance relies on ultrasonography and serum alpha-fetoprotein (AFP), yet AFP exhibits limited sensitivity and specificity for early HCC. Emerging non-coding RNAs, particularly tRNA-derived small RNAs (tsRNAs), offer stable, detectable alternatives for liquid biopsy. Among these, 5′-tiRNA-Lys-CTT, a 5′-tRNA half derived from tRNA-Lys-CTT, has shown promise. This commentary explores the potential of 5′-tiRNA-Lys-CTT, a tRNA-derived small RNA (tsRNA), as an emerging biomarker for early HCC detection. It integrates biology, diagnostic performance along with recent advancements in tsRNA research for Hepatocellular carcinoma (HCC), and discusses potential clinical applications for enhanced early detection and personalized therapy. Ultimately, 5′-tiRNA-Lys-CTT represents a promising avenue for liquid biopsy-based screening, potentially revolutionizing HCC management.